Status:

COMPLETED

Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence

Lead Sponsor:

US Department of Veterans Affairs

Conditions:

Fecal Incontinence

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this study is to evaluate and compare treatment with fiber and loperamide for fecal incontinence.

Detailed Description

Fecal incontinence (FI) affects 4-24% adults in the community and greatly impacts quality of life. Both fiber and loperamide are common, first-line treatments for diarrhea-associated FI in primary car...

Eligibility Criteria

Inclusion

  • weekly fecal incontinence

Exclusion

  • fecal impaction
  • inability to complete a baseline 1-week bowel diary
  • rectal prolapse
  • any prior radiation to the pelvis
  • colo-rectal cancer
  • rectal fistula
  • inflammatory bowel disease
  • neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease)
  • constipation (\<2 bowel movements/week) or total colectomy

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00727649

Start Date

July 1 2008

End Date

December 1 2013

Last Update

April 1 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Birmingham

Birmingham, Alabama, United States, 35233

Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence | DecenTrialz